JP7470708B2 - 芳香族誘導体、その調製方法および医薬用途 - Google Patents

芳香族誘導体、その調製方法および医薬用途 Download PDF

Info

Publication number
JP7470708B2
JP7470708B2 JP2021552591A JP2021552591A JP7470708B2 JP 7470708 B2 JP7470708 B2 JP 7470708B2 JP 2021552591 A JP2021552591 A JP 2021552591A JP 2021552591 A JP2021552591 A JP 2021552591A JP 7470708 B2 JP7470708 B2 JP 7470708B2
Authority
JP
Japan
Prior art keywords
foregoing
pharma
compound
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522890A (ja
JP2022522890A5 (cg-RX-API-DMAC7.html
Inventor
ディン ワン,
ニン シャオ,
ホンビン ユアン,
フランク カイザー,
Original Assignee
バイオアーディス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオアーディス エルエルシー filed Critical バイオアーディス エルエルシー
Publication of JP2022522890A publication Critical patent/JP2022522890A/ja
Publication of JP2022522890A5 publication Critical patent/JP2022522890A5/ja
Application granted granted Critical
Publication of JP7470708B2 publication Critical patent/JP7470708B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2021552591A 2019-03-05 2020-02-19 芳香族誘導体、その調製方法および医薬用途 Active JP7470708B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/076926 2019-03-05
PCT/CN2019/076926 WO2020177067A1 (en) 2019-03-05 2019-03-05 Aromatic derivatives, preparation methods, and medical uses thereof
PCT/CN2020/075849 WO2020177534A1 (en) 2019-03-05 2020-02-19 Aromatic derivatives, preparation methods, and medical uses thereof

Publications (3)

Publication Number Publication Date
JP2022522890A JP2022522890A (ja) 2022-04-20
JP2022522890A5 JP2022522890A5 (cg-RX-API-DMAC7.html) 2023-02-28
JP7470708B2 true JP7470708B2 (ja) 2024-04-18

Family

ID=72337401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552591A Active JP7470708B2 (ja) 2019-03-05 2020-02-19 芳香族誘導体、その調製方法および医薬用途

Country Status (10)

Country Link
US (1) US11976058B2 (cg-RX-API-DMAC7.html)
EP (1) EP3935048A4 (cg-RX-API-DMAC7.html)
JP (1) JP7470708B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210135558A (cg-RX-API-DMAC7.html)
CN (1) CN111902400B (cg-RX-API-DMAC7.html)
CA (1) CA3132405A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552133A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109522VA (cg-RX-API-DMAC7.html)
TW (1) TWI860334B (cg-RX-API-DMAC7.html)
WO (2) WO2020177067A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12595370B2 (en) 2018-03-02 2026-04-07 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US10935695B2 (en) 2018-03-02 2021-03-02 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US12595371B2 (en) 2018-03-02 2026-04-07 Johnson & Johnson Vision Care, Inc. Contact lens with improved vision break-up time
US12674032B2 (en) 2019-06-28 2026-07-07 Johnson & Johnson Vision Care, Inc. Polymerizable fused tricyclic compounds as absorbers of UV and visible light
US20220194944A1 (en) * 2020-12-18 2022-06-23 Johnson & Johnson Vision Care, Inc. Photostable mimics of macular pigment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
JP2015523383A (ja) 2012-07-11 2015-08-13 ブループリント メディシンズ コーポレイション 線維芽細胞成長因子受容体の阻害剤
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
JP2016519673A (ja) 2013-03-15 2016-07-07 セルジーン アビロミクス リサーチ, インコーポレイテッド ヘテロアリール化合物およびそれらの使用
CN107286130A (zh) 2016-04-13 2017-10-24 成都融科博海科技有限公司 一种激酶选择性抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012271357A1 (en) 2011-06-16 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
JP6655559B2 (ja) 2014-06-24 2020-02-26 コベストロ、ドイチュラント、アクチエンゲゼルシャフトCovestro Deutschland Ag ジフェニルメタン系ジアミンおよびポリアミンの製造方法
EP3029864B1 (en) 2014-12-01 2020-11-18 Harman Becker Automotive Systems GmbH Fast representation of station information in a fm receiver using a single tuner
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) * 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN105906630B (zh) 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
RU2747260C2 (ru) * 2016-12-19 2021-04-29 Аббиско Тхерапеутицс Цо., Лтд. Ингибитор рфрф4, способ его получения и его фармацевтическое применение
CN110997637B (zh) * 2017-09-05 2022-09-27 保仕健生物科技(上海)有限公司 芳香类衍生物、其制备方法及其在医药上的应用
CN109224235B (zh) 2018-10-23 2020-05-19 孙喜家 一种双腔管
CN109331654A (zh) 2018-10-26 2019-02-15 高邮高和光电器材有限公司 一种有机废气光催化氧化装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523383A (ja) 2012-07-11 2015-08-13 ブループリント メディシンズ コーポレイション 線維芽細胞成長因子受容体の阻害剤
JP2016519673A (ja) 2013-03-15 2016-07-07 セルジーン アビロミクス リサーチ, インコーポレイテッド ヘテロアリール化合物およびそれらの使用
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107286130A (zh) 2016-04-13 2017-10-24 成都融科博海科技有限公司 一种激酶选择性抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shraga, Amit et al.,Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor,Cell Chemical Biology,2019年,26(1),98-108

Also Published As

Publication number Publication date
SG11202109522VA (en) 2021-09-29
WO2020177067A1 (en) 2020-09-10
US20220169634A1 (en) 2022-06-02
CN111902400A (zh) 2020-11-06
US11976058B2 (en) 2024-05-07
WO2020177534A1 (en) 2020-09-10
PH12021552133A1 (en) 2022-08-22
CA3132405A1 (en) 2020-09-10
EP3935048A1 (en) 2022-01-12
EP3935048A4 (en) 2022-11-09
KR20210135558A (ko) 2021-11-15
TWI860334B (zh) 2024-11-01
JP2022522890A (ja) 2022-04-20
TW202100514A (zh) 2021-01-01
CN111902400B (zh) 2024-08-30

Similar Documents

Publication Publication Date Title
US12083124B2 (en) Bicyclic heterocycles as FGFR inhibitors
WO2024218686A1 (en) Pyrido[4,3-d]pyrimidine compounds
WO2024213979A1 (en) Pyrido[4,3-d]pyrimidine compounds
EP4551296A1 (en) Pyrido[4,3-d]pyrimidine compounds
US11976058B2 (en) Aromatic derivatives, preparation methods, and medical uses thereof
US20250034173A1 (en) Pyrido[4,3-d]pyrimidine compounds
WO2025101776A1 (en) Heterocycles and uses thereof
US12263171B2 (en) 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
JP2025100453A (ja) ピリド[4,3-d]ピリミジン化合物
JP2018507214A (ja) Fgfr4阻害剤としての二環式複素環
US12428420B2 (en) Tricyclic heterocycles as FGFR inhibitors
US20230399327A1 (en) High activity hpk1 kinase inhibitor
US20240083898A1 (en) Tricyclic triazolo compounds as dgk inhibitors
US12600723B2 (en) Tetracyclic compounds as DGK inhibitors
WO2024003773A1 (en) 2,7-naphthyridine compounds as mastl inhibitors
US11377444B2 (en) Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors
WO2020198067A1 (en) Pkm2 modulators and methods for their use
HK40040054A (en) Aromatic derivatives, preparation methods, and medical uses thereof
HK40040054B (en) Aromatic derivatives, preparation methods, and medical uses thereof
US20250163059A1 (en) Heterocyclic kinase inhibitors
TW202545531A (zh) 氮—喹唑啉化合物之使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240321

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240408

R150 Certificate of patent or registration of utility model

Ref document number: 7470708

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150